Overview

Pioneer Psychedelic-Assisted Therapy with Precision Pharmacogenomics

Optimize psychedelic treatments, mitigate risks, and enhance mental health outcomes across your health system.

Overview

Emerging research on psychedelics—such as psilocybin, LSD, ketamine, and MDMA—highlights their transformative potential in treating mental health conditions. PGxAI's Psychedelics module (PGxHypnos™) integrates advanced pharmacogenomics and real-world clinical data to guide the safe, personalized use of psychedelic substances in therapy. By analyzing each patient's genetic markers and psychological profile, PGxHypnos™ helps providers mitigate risks, tailor dosages, and maximize therapeutic benefits for conditions like treatment-resistant depression, PTSD, and anxiety disorders.

•

Coverage of key psychedelics, including psilocybin, LSD, MDMA, DMT, ketamine, and more.

•

Analysis of critical genetic markers (e.g., 5-HT receptors, CYP2D6, SLC6A4) influencing psychedelic response.

•

AI-driven insights updated in real time, supporting safe and effective psychedelic-assisted treatments.

Key Highlights

Serving every stakeholder in healthcare

Schedule a Demo Contact Us

Real-World Evidence

Ongoing machine learning integrates outcomes from multiple centers, continuously refining recommendation accuracy.

Risk Mitigation

Helps identify predispositions to anxiety, psychosis, or adverse reactions, allowing clinicians to take preventative measures.

Personalized Psychedelic Journey

Aligns specific substances, dosages, and therapy protocols with the patient's genetic and clinical profile.

Regulatory & Ethical Compliance

Designed to align with emerging clinical guidelines for psychedelic-assisted therapies, ensuring responsible and data-driven practices.

Clinical Impact

Maximize Clinical Impact with PGXAI

Schedule a Demo Contact Us

Accelerated Therapeutic Response

Patients often experience faster relief from depression, PTSD, and other conditions when therapy is matched to their genetic profile.

Reduced Adverse Events

Comprehensive genetic insights minimize risks like severe anxiety or psychosis that can arise from psychedelic sessions.

Enhanced Multidisciplinary Collaboration

Psychiatrists, therapists, and pharmacists coordinate better with unified, real-time PGx data.

Future-Focused Care

Positions your institution at the forefront of the evolving psychedelic therapy landscape, attracting research grants and early adopters.

Drug Categories

PGxAI supports a spectrum of psychedelic therapies

Schedule a Demo Contact Us

Classic Psychedelics:

LSD, Psilocybin, Mescaline

Entactogens:

MDMA (3,4-Methylenedioxymethamphetamine)

Dissociatives:

Ketamine, Dextromethorphan

Short-Acting Tryptamines:

DMT, 5-MeO-DMT

Atypical Compounds:

Salvia divinorum, Ibogaine. Each recommendation factors in pharmacogenetic markers tied to serotonin receptors, metabolism enzymes, and neurotransmitter transporters.

Case Study

New Horizons Psychedelic Clinic

Schedule a Demo Contact Us

Challenge

Inconsistent responses and occasional severe anxiety in patients receiving ketamine infusions for treatment-resistant depression.

Solution

PGxHypnos™ integrated to analyze genetic factors related to serotonin receptors and metabolism.

Results

30% improvement in remission rates, reduced incidence of high-anxiety reactions, and more predictable session outcomes.

What's next

Ready to Shape the Future of Precision Medicine?

Empower your mental health and research teams with AI-driven pharmacogenomics that refine psychedelic-assisted therapy, bolster patient safety, and enhance clinical success.

Request a Demo

See how PGxHypnos™ integrates into psychedelic therapy workflows.